Methods to impair hematologic cancer progenitor cells and compounds related thereto
View Patent ↗Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3Rα or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.
1. A method for impairing cancerous progenitor cells, which express CD123, but do not significantly express CD131, in a patient in need thereof, comprising introducing to the patient's bone marrow or peripheral blood a composition comprising an antibody conjugated to a cytotoxic agent, wherein said antibody binds selectively to CD123.
2. The method of claim 1 , wherein the cancerous progenitor cells do not significantly express CD131 as examined by flow cytometry.
3. The method of claim 1 , wherein the antibody is a monoclonal antibody, F(ab′) 2 , Fab or Fv.
4. The method of claim 1 , wherein the cytotoxic agent is a chemotherapeutic agent, a plant-derived toxin, a fungus-derived toxin, a bacteria-derived toxin or a radioisotope.
5. The method of claim 4 , wherein the bacteria-derived toxin is a deglycosylated ricin A chain, a ribosome inactivating protein, alpha-sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin or Pseudomonas exotoxin.
6. The method of claim 1 , wherein the cytotoxic agent is a hormone, an antimetabolite, an alkylating agent, a coagulant, a cytokine, a growth factor, a bacterial endotoxin, the lipid A moiety of a bacterial endotoxin or a cytotoxin.
7. The method of claim 4 , wherein the chemotherapeutic agent is a steroid, cytosine, arabinoside, fluorouracil, methotrexate, aminopterin, an anthracycline, mitomycin C, a ymca alkaloid, demecolcine, etoposide, mithramycin, calicheamicin, CC-1065, chiorambucil or meiphalan.
8. The method of claim 4 , wherein the radioisotope is an alpha-emitting radioisotope or a beta-emitting radioisotope.
9. The method of claim 1 , wherein the patient is human.
10. A method for impairing cancerous progenitor cells, which express CD123, but do not express CD131 as examined by flow cytometry, in a patient in need thereof, comprising introducing to the patient's bone marrow or peripheral blood a composition comprising a conjugate, wherein the conjugate comprises a cytotoxic agent and an antibody that binds to CD123.
11. The method of claim 10 , wherein the antibody selectively binds to CD123.